His work over the last two decades has been centered on the production and role of beta amyloid in Alzheimer's disease. Based in part on a series of screens in pre-clinical models, three compounds, R-flurbiprofen, curcumin and DHA are already in or under serious consideration for clinical trials. His recent papers investigate the potential for AD prevention with omega 3 fatty acid (DHA, docosahexaenoic acid from fish) and the curry spice extract, curcumin, to control inflammation and oxidative damage and act directly on insoluble amyloid fibrils in plaques and more soluble toxic species in vitro and in vivo. They also explore the role of omega 3 and other dietary fatty acids control the neuroprotective PI3-kinase>Akt pathway, synaptic protein loss, amyloid and cognitive deficits. Other recent contributions include the co-development of amyloid and tangle PET imaging probes with UCLA colleagues. Much of his work is based on an analysis of environmental risk factors, notably NSAIDs, fats and antioxidants and other anti-amyloid agents for efficacy in animal models for the disease. The primary goal of his lab is to develop safe and widely available methods for the prevention of Alzheimer's and possibly other degenerative diseases of aging.